BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF)

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Gane, Edward J. ^{[3
]}

Agarwal, Kosh ^{[4
]}

Wong, Grace Lai-Hung C. ^{[5
]}

Lim, Young-Suk ^{[6
]}

Chen, Chi-Yi ^{[7
]}

Lim, Seng Gee ^{[8
]}

Yatsuhashi, Hiroshi ^{[9
]}

Fung, Scott K. ^{[10
]}

Abramov, Frida ^{[11
]}

Wang, Hongyuan ^{[11
]}

Yee, Leland J. ^{[11
]}

Flaherty, John F. ^{[11
]}

Pan, Calvin Q. ^{[12
]}

Marcellin, Patrick ^{[13
]}

机构：

[1] Hosp Univ Vall Dhebron, Barcelona, Spain

[2] Ciberehd Inst Carlos III, Madrid, Spain

[3] Univ Auckland, Auckland, New Zealand

[4] Kings Coll Hosp London, Inst Liver Studies, London, England

[5] Chinese Univ Hong Kong, MDAC, Hong Kong, Peoples R China

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[7] Chiayi Christian Hosp, Chiayi, Taiwan

[8] Natl Univ Hlth Syst, Singapore, Singapore

[9] Natl Hosp Org Nagasaki Med Ctr, Clin Res Ctr, Nagasaki, Japan

[10] Univ Toronto, Dept Med, Toronto, ON, Canada

[11] Gilead Sci Inc, Foster City, CA 94404 USA

[12] NYU, NYU Langone Hlth, Grossman Sch Med, New York, NY USA

[13] Univ Paris, Hop Beaujon, AP HP, Paris, France

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1405C

引用

页码：S507 / S509

页数：3

共 50 条

[31] COMPARATIVE SAFETY OF TENOFOVIR DISOPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS [J].

Yu, N. Y. ;

Chang, K. C. .

VALUE IN HEALTH, 2020, 23 :S532-S532

[32] Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF) [J].

Chuang, Wan-Long ;

Seto, Wai-Kay ;

Inokuma, Tetsuro ;

Ikeda, Fusao ;

Santantonio, Teresa A. ;

Flaherty, John F. ;

Kim, Kyungpil ;

Gaggar, Anuj ;

Subramanian, Mani ;

Habersetzer, Francois ;

Ramji, Alnoor ;

Mukewar, Shrikant ;

Chan, Henry Lik-Yuen ;

Brunetto, Mau-rizia R. .

HEPATOLOGY, 2016, 64 :916A-917A

[33] EFFICACY AND SAFETY RESULTS 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) VS CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB) [J].

Lampertico, Pietro ;

Buti, Maria ;

Fung, Scott ;

Ahn, Sang Hoon ;

Chuang, Wan-Long ;

Tak, Won Young ;

Ramji, Alnoor ;

Chen, Chi-Yi ;

Tam, Edward ;

Bae, Ho ;

Ma, Xiaoli ;

Flaherty, John F. ;

Gaggar, Anuj ;

Lau, Audrey H. ;

Feierbach, Becket ;

Wu, George ;

Suri, Vithika ;

Subramanian, Mani ;

Trinh, Huy N. ;

Yoon, Seung-Kew ;

Agarwal, Kosh ;

Lim, Young-Suk ;

Chan, Henry L. .

GASTROENTEROLOGY, 2019, 156 (06) :S1195-S1195

[34] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-POSITIVE PATIENTS: A GLOBAL PHASE 3 STUDY [J].

Agarwal, Kosh ;

Fung, Scott ;

Seto, Wai-Kay ;

Lim, Young-Suk ;

Gane, Edward ;

Janssen, Harry L. ;

Chuang, Wan-Long ;

Bae, Ho ;

Yoon, Ki Tae ;

Flaherty, John F. ;

Lau, Audrey ;

Gaggar, Anuj ;

Suri, Vithika ;

Cathcart, Andrea ;

Lin, Lanjia ;

Chan, Alain ;

Shalimar, Mani Subramanian ;

Furusyo, Norihiro ;

Buti, Maria ;

Chan, Henry L. .

GASTROENTEROLOGY, 2017, 152 (05) :S1085-S1086

[35] IMPACT OF PRE-TREATMENT PLASMA HBV DNA LEVELS ON THE RATE OF ALT NORMALIZATION DURING ANTIVIRAL THERAPY WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR CHRONIC HEPATITIS B (CHB) [J].

Lim, Young-Suk ;

Choi, Jonggi ;

Choi, Won-Mook ;

Brunetto, Maurizia R. ;

Hou, JinLin ;

Agarwal, Kosh ;

Chang, Ting-Tsung ;

Ning, Qin ;

Lim, Seng Gee ;

Streinu-Cercel, Adrian ;

Flaherty, John F. ;

Wang, Hongyuan ;

Gao, Bing ;

Gaggar, Anuj ;

Suri, Vithika ;

Coffin, Carla S. ;

Ferrety, Maria Asuncion Buti ;

Chan, Henry Lik Yuen .

HEPATOLOGY, 2020, 72 :485A-485A

[36] Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks [J].

Chuang, W. L. ;

Agarwal, K. ;

Hwang, J. S. ;

Caruntu, F. ;

Wong, F. ;

Hann, H. W. ;

Flaherty, J. ;

Lau, A. ;

Gaggar, A. ;

Suri, V. ;

Mo, S. ;

Subramanian, G. M. ;

Hui, A. J. ;

Yatsuhashi, H. ;

Lim, Y. S. .

JOURNAL OF HEPATOLOGY, 2017, 66 (01) :S695-S695

[37] Eligibility of patients in a community HIV setting for switching rilpivirine/emtricitabine/tenofovir disoproxil fumarate (R/F/TDF) to tenofovir alafenamide(TAF) [J].

Goorney, B. ;

Perez, K. .

HIV MEDICINE, 2019, 20 :39-39

[38] TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS [J].

Buti, M. ;

Hadziyannis, S. ;

Mathurin, P. ;

Urbanek, P. ;

Sherman, M. ;

Strasser, S. ;

Wang, C. ;

Petersen, J. ;

Heathcote, E. J. ;

Marcellin, P. ;

Sorbel, J. ;

Mondou, E. ;

Anderson, J. ;

Rousseau, F. .

JOURNAL OF HEPATOLOGY, 2009, 50 :S10-S11

[39] A PHASE 3 STUDY COMPARING SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) WITH CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB): WEEK 48 EFFICACY AND SAFETY RESULTS [J].

Chan, Henry Lik Yuen ;

Lampertico, Pietro ;

Buti, Maria ;

Fung, Scott ;

Ahn, Sang Hoon ;

Chuang, Wan-Long ;

Tak, Won Young ;

Ramji, Alnoor ;

Chen, Chi-Yi ;

Tam, Edward ;

Bae, Ho ;

Ma, Xiaoli ;

Flaherty, John ;

Gaggar, Anuj ;

Lau, Audrey ;

Feierbach, Becket ;

Wu, George ;

Suri, Vithika ;

Subramanian, Mani ;

Huy Trinh ;

Yoon, Seung-Kew ;

Agarwal, Kosh ;

Lim, Young-Suk .

GUT, 2019, 68 :A142-A143

[40] Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis [J].

Strasser, S. I. ;

Gane, E. J. ;

Weilert, F. ;

Sievert, W. ;

George, J. ;

Crawford, D. ;

Ngu, M. C. ;

Heathcote, E. J. ;

Marcellin, P. ;

Sorbel, J. ;

Rousseau, F. .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 :A309-A309

← 1 2 3 4 5 →